Physician profile
Mark Deuber
NPI 1356443964
$10,708.89
in general payments reported to CMS, 2019-2025
11 companies · $820 in 2025
The $820 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,161 · 2020: $725 · 2021: $856 · 2022: $1,046 · 2023: $1,078 · 2024: $1,023 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,799.33 | 2019-2022 | |
| Lumenis, INC | $2,500.00 | 2019 | |
| Abbvie INC. | $1,853.75 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Botox |
| Merz North America, INC. | $1,714.26 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $813.14 | 2019-2025 | Dysport |
| Mentor Worldwide LLC | $527.61 | 2019-2025 | Mentor Siltex Round Spectrum, Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander |
| Sientra, INC. | $185.65 | 2021-2022 | |
| Acera Surgical, INC. | $108.91 | 2024 | Restrata Wound Matrix |
| Tela Bio, INC. | $99.01 | 2024 | Ovitex 2s |
| Revance Therapeutics, INC. | $79.63 | 2024-2025 | Daxxify |
| Acacia Pharma INC | $27.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Deuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.